W.L. Gore & Associates today released data from a long-term study of its Gore Bio-A tissue reinforcement bioabsorbable mesh designed to treat complex ventral hernias in patients with contaminated fields. The study was published in the Annals of Surgery.
Gore’s Bio-A is designed as a web of biocompatible synthetic polymers that are gradually reabsorbed into the body while facilitating tissue generation and healing, according to the company.
The study, which enrolled over 100 subjects, reported a lowered recurrence rate at 17% after 24 months in patients treated with the Gore Bio-A, versus a 39% recurrence rate in patients treated with a biologic mesh.
“I think this study represents an important step forward in defining the most appropriate way to reconstruct complex abdominal wall defects. Bio A performed very well in this challenging group of patients and will provide a cost-effective alternative for reconstructive surgeons,” lead investigator Dr. Michael Rosen of the Cleveland Clinic said in a press release.
Patients treated with Gore’s mesh also reported higher quality of life scores, and faced lessened long-term complications as the mesh did not have to be removed at a later date, Gore said.
“This study proves for the first time something we have believed all along: a biosynthetic mesh can be equivalent or better than a biologic. By being both more cost effective for hospitals and payors while also improving quality of life for patients, GORE BIO-A Tissue Reinforcement is truly advancing healthcare and the way we treat CVH,” general surgical products biz unit leader Ron Anderson said in prepared remarks.